Bionomics : to Feature at Neuroscience Innovation Forum and Biotech Showcase in San Francisco

ABN 53 075 582 740

ASX ANNOUNCEMENT

5 January 2018

BIONOMICS TO FEATURE AT NEUROSCIENCE INNOVATION

FORUM AND BIOTECH SHOWCASE IN SAN FRANCISCO

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, advises that it will provide corporate presentations at two upcoming events in San Francisco:

• o The Neuroscience Innovation Forum on Sunday 7th January, 2018 at 3:50pm (PST), at the Marine's Memorial Club,

• o The Biotech Showcase™ 2018 on Monday 8th January, 2018 at 3:30pm (PST), at the Hilton San Francisco Union Square.

Bionomics' CEO & Managing Director Dr Deborah Rathjen will also participate in a Neuroscience Innovation Forum panel discussion, "New Approaches to Neuropsychiatry and Pain Management", at 11:25am on Sunday 7th January, 2018 at the Marine's Memorial Club.

Both events coincide with the 36th Annual JP Morgan Healthcare Conference and associated life sciences investment and partnering meetings.

The Neuroscience Innovation Forum has attracted high calibre industry Key Opinion Leaders and experts and offers numerous partnering meeting opportunities. The agenda can be found by copying the following to your web browserhttp://www.sachsforum.com/nif-about.html.

The Biotech Showcase™ is expected to attract over 3,500 attendees, including 400 presenting companies and over 900 investors.

Bionomics' presentations will provide an overview of the Company's BNC210 program. BNC210 is currently undergoing a Phase 2 clinical trial in patients suffering Post-Traumatic Stress Disorder (PTSD).

The presentations will also highlight Bionomics' collaboration with Merck & Co (known as MSD outside the US and Canada) in cognition.

Meetings held with investors and pharma companies during the week will encompass Bionomics' robust pipeline with the objective of advancing partnering and clinical development.

A copy of the corporate presentation can be found on Bionomics' website,www.bionomics.com.au

FOR FURTHER INFORMATION PLEASE CONTACT:
Australia	US
Monsoon Communications	Stern Investor Relations
Rudi Michelson	Beth DelGiacco
[phone]	[phone]
[e-mail]	[e-mail]
About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanised monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210, BNC101 and BNC105), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.